EFFICACY OF FRONTALIS MUSCLE FLAP SUSPENSION  IN TREATING MODERATE TO SEVERE BLEPHAROPTOSIS

Purpose: This study aims to evaluate the efficacy of frontalis muscle flap suspension in treating moderate to severe blepharoptosis. Study subjects: 54 eyes of 47 moderate to severe blepharoptosis patients (aged 17.34 ± 9.17 years, 18 males, 29 females). Study design: Prospective uncontrolled clinical trial. Results: Following frontalis muscle flap suspension surgery, there was a statistically significant improvement (p<0.001) in margin reflex distance 1 (MRD1) and palpebral fissure height (PFH), from 0.009 ± 0.60 mm and 5.59 ± 0.68 mm (pre-operation) to 2.68 ± 1.10 mm and 8.26 ± 1.14 mm (1 week after operation), 3.63 ± 0.77 mm and 9.24 ± 0.85 mm (6 months after operation), 3.45 ± 0.80 mm and 9.02 ± 0.89 mm (12 months after operation). At the 12th month after operation, it was found that severe lagophthalmos, lid lag on down-gaze and forehead hypoesthesia were present in 7.4%, 9.3% and 14.0% of all treated eyes, respectively. Excellent functional results were determined in 66,0% of procedures postoperatively, with 31,9% and 2,1% rated as good and unsatisfactory. In terms of cosmetic results, 78,7%, 19,1% and 2,1% of cases were rated as excellent, good and unsatisfactory, respectively. Conclusion: Majority of case results were excellent (78,7%) and good (19,1%), unsatisfactory cases 2,1%.

Download Full-text

Ataluren: Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Neuropediatrics ◽

10.1055/s-0036-1583648 ◽

2016 ◽

Vol 47 (S 01) ◽

Author(s):

U. Schara ◽

C. McDonald ◽

K. Bushby ◽

M. Tulinius ◽

R. Finkel ◽

...

Keyword(s):

Clinical Trial ◽

Duchenne Muscular Dystrophy ◽

Muscular Dystrophy ◽

Nonsense Mutation ◽

Clinical Trial Results

Download Full-text

Right and left comparison clinical trial results by open trial using Hirudoid ointment and vitamin A oil ointment in marketing for drying dermatosis.

Nishi Nihon Hifuka ◽

10.2336/nishinihonhifu.57.311 ◽

1995 ◽

Vol 57 (2) ◽

pp. 311-314

Author(s):

KIYOSHI KAGAMI

Keyword(s):

Clinical Trial ◽

Vitamin A ◽

Open Trial ◽

Clinical Trial Results

Download Full-text

Clinical trial results of Hydrocel for donor sites and thermal burns.

Nishi Nihon Hifuka ◽

10.2336/nishinihonhifu.60.206 ◽

1998 ◽

Vol 60 (2) ◽

pp. 206-211 ◽

Cited By ~ 2

Author(s):

TERUO UENO

Keyword(s):

Clinical Trial ◽

Thermal Burns ◽

Clinical Trial Results

Download Full-text

Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials

Mini-Reviews in Medicinal Chemistry ◽

10.2174/1389557521666201222145842 ◽

2020 ◽

Vol 21 ◽

Author(s):

Subha Sankar Paul ◽

Goutam Biswas

Keyword(s):

Public Health ◽

Clinical Trial ◽

Clinical Trials ◽

Small Molecule ◽

Mode Of Action ◽

Antiviral Drugs ◽

Public Health Emergency ◽

Advanced Stage ◽

Clinical Trial Results

: COVID-19 is a public health emergency of international concern. Although, considerable knowledge has been acquired with time about the viral mechanism of infection and mode of replication, yet no specific drugs or vaccines have been discovered against SARS-CoV-2, till date. There are few small molecule antiviral drugs like Remdesivir and Favipiravir which have shown promising results in different advanced stage of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir-Ritonavir combination, although initially was hypothesized to be effective against SARS-CoV-2, are now discontinued from the solidarity clinical trials. This review provides a brief description of their chemical syntheses along with their mode of action and clinical trial results available in Google and different peer reviewed journals till 24th October 2020.

Download Full-text

The Disclosure Decision of Foreign Clinical Trials in China: Moderating Effects of Firms’ Contingencies

SAGE Open ◽

10.1177/21582440211016380 ◽

2021 ◽

Vol 11 (2) ◽

pp. 215824402110163

Author(s):

Tariq H. Malik ◽

Chunhui Huo

Keyword(s):

Clinical Trial ◽

Clinical Trials ◽

Risk Taking ◽

Academic Community ◽

Moderating Effects ◽

The Public ◽

Industrial Enterprises ◽

Unit Increase ◽

Clinical Trial Results ◽

Clinical Trial Activity

Result disclosure of clinical trial posts a conflicting logic between private secrecy and public interest. Despite ethical and legal requirements for disclosing clinical trial results, clinical trials’ sponsors tend to withhold the results. We explored the location, timing, and rationale behind the withheld clinical trial results. Based on the entrepreneurial orientation (EO) perspective, we propose that organizational EO contingencies moderate the disclosure decision. We used the completed clinical trial projects in China by foreign and domestic sponsors. First, we found that a unit increase in the sponsor’s experience can increase the disclosure about 1.01 times. Second, we found that industrial enterprises disclose results about 3.7 times more than universities do. Third, we found that foreign clinical trial projects in China tend to disclose 3.9 times more than domestic projects. We link these findings to two types of audience. First, we inform the academic community on the theory and empirics regarding risk-taking behavior in the biopharmaceutical industry’s clinical trial activity. Second, we address the general audiences concerned about the ethical and socioeconomic wellbeing of the public.

Download Full-text